Safety of Chronic Simvastatin Treatment in Patients with Decompensated Cirrhosis: Many Adverse Events but No Liver Injury
ConclusionsChronic treatment with simvastatin 40 mg/day in patients with decompensated cirrhosis was associated with several adverse events, being MI the only clinically significant one, which appears to be related to the simvastatin dosage and the degree of cirrhosis severity. Noticeably, no liver injury was recorded.
Source: Digestive Diseases and Sciences - Category: Gastroenterology Source Type: research
More News: Cardiology | Cardiovascular | Children | Cholesterol | Cirrhosis | Gastroenterology | Headache | Heart | Liver | Migraine | Simvastatin | Statin Therapy | Toxicology | Urology & Nephrology | Zocor